Showing 1 - 5 results of 5 for search 'Jürgen Kuball', query time: 0.02s Refine Results
  1. 1
    CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy: Collaborative translation of scientific discoveries into advanced treatments for neurological rare genetic diseases and cancer

    CTGCT, Centre of Excellence for the Technologies of Gene and Cell Therapy: Collaborative translation of scientific discoveries into advanced treatments for neurological rare geneti... by Darja Marolt Presen, Duško Lainšček, Jane Kinghorn, Zsolt Sebestyen, Jurgen Kuball, Leila Amini, Petra Reinke, Anke Fuchs, Roman Jerala, Mojca Benčina

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation

    Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation by Konradin F. Müskens, Winny N. R. Collot‐d'Escury, Rana Dandis, Saskia Haitjema, Jürgen Kuball, Moniek A. deWitte, Marc Bierings, Caroline A. Lindemans, Stefan Nierkens, Mirjam E. Belderbos

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

    Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML by Zsolt Sebestyen, Jürgen Kuball, Maud Plantinga, Anja Krippner-Heidenreich, S Nierkens, Ester Dunnebach, Vania Lo Presti, Olaf T Heidenreich, Angelo Meringa, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Annelisa Cornel, Niek P van Til

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial

    Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial by Annoek E. C. Broers, Ellen Meijer, Bronno van der Holt, Cornelis N. de Jong, Erfan Nur, Geerte L. van Sluis, Goda Choi, Michel van Gelder, Johan A. Maertens, Jürgen Kuball, Dries Deeren, Heleen A. Visser‐Wisselaar, Lamberdina A. H. M. Meulendijks, Jan J. Cornelissen, the HOVON Stem Cell Transplantation Working Group

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1

    Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1 by Aimee du Chatinier, Zsolt Sebestyen, Jürgen Kuball, Stefan Nierkens, Anja Krippner-Heidenreich, Yuyan Lu, Ana P Lopes, Ester Dunnebach, Denise A M H van den Beemt, Sebastiaan van Heesch, Annelisa M. Cornel, Loutje van der Sman, Jip T van Dinter, Marta Arrabito, Marliek van Hoesel, Thomas A Kluiver, Noël M M Dautzenberg, Linde Dekker, Jorik M van Rijn, Juliane L Buhl, Farnaz Barneh, Luca Lo Nigro, Esther Hulleman, Jarno Drost, Olaf T Heidenreich, Weng Chuan Peng

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: